GPT, Rosalind, and the Generic Drug Question: What OpenAI’s Life Sciences Model Really Changes
The life sciences industry loves a good “breakthrough” story. But the real question isn’t whether AI can generate text, summarize papers, or even draft candi…

The patent cliff isn’t just a legal event—it’s a commercial deadline.
Most teams treat “LOE” (loss of exclusivity) as a moment in time: the day the last patent expires, the day generics arrive, the day revenue starts to slide. But in payer-driven mar…

OpenAI’s GPT just did something that sounds like science fiction—but the market impact is very real: it “smashed” drug patent cliffs and reportedly accelerated the discovery of new drug candidates by as much as 70%. That’s the headline. The deeper stor…

Predict the Attack: How to Forecast Paragraph IV Patent Challenges and Neutralize “Skinny Label” Threats
If you work in pharma strategy, legal, or commercial planning, you already know the uncomfortable truth: the most damaging competitive moves rarely…

Your drug’s “patent life” isn’t one number—it’s a moving target across the GCC. Here’s how to know exactly how long it lasts.
In the GCC, the difference between a blockbuster and a generic wave often comes down to timing.
Not the timing of clinical tri…

Unlocking the Hidden Timeline: How Long Do Drug Patents Last in the GCC?
Imagine investing millions into developing a groundbreaking medication, only to find out that your exclusive rights could expire sooner than expected, or worse, that your competit…

Your competitor isn’t “just being careful.” They’re extending the drug’s life. Here are 4 signals to watch.
In pharma, time is the real currency. Not just time in the clinic—but time on the patent clock, time in the regulatory queue, and time before ge…

Biopharma teams don’t lose deals because they lack ambition. They lose because they’re pitching the wrong story at the wrong time.
In licensing, partnering, and commercial strategy, timing is everything. Yet too many BizDev and packaging teams still op…

OpenAI’s “GPT for Life Sciences” is getting the hype cycle treatment. But the real question isn’t whether the model can generate text—it’s what it changes in the drug development pipeline when the novelty wears off.
Because in pharma, the bottleneck ra…

Biosimilar timing isn’t a calendar problem—it’s a procurement problem.
Most teams treat patent expiry intelligence like a countdown clock: identify the likely expiry date, map the regulatory pathway, and then wait for the market to open.
That approach …